Hormonal therapy might be a better choice asmaintenance treatment thancapecitabine afterresponse toifrst-line capecitabine-based combination chemotherapy forpatients withhormone receptor-positive andHER2-negative, metastatic breast cancer
combination chemotherapy、metastatic breast cancer、growth factor receptor、estrogen receptor、overall survival、Medical Sciences、clinical trials、adverse events
35
R73;R71
2016-07-15(万方平台首次上网日期,不代表论文的发表时间)
共7页
310-316